Navigation Links
IDM Pharma Reports 2008 Financial Results
Date:3/31/2009

ith the approval of MEPACT in Europe, many young patients and their families have a new treatment option for this devastating disease for the first time in nearly 20 years. We wish to thank the many patients, their families, patient advocates, clinicians and the European regulators who were instrumental in the approval of MEPACT. As we complete our evaluation of the strategic options available to the Company, we continue to believe that the survival benefit of MEPACT warrants U.S. regulatory approval as well and that it should ultimately be made available to patients."

Details of Financial Results

Total revenues in the quarter ended December 31, 2008 were $0.3 million compared to total revenues of $5.6 million for the quarter ended December 31, 2007. Total revenues were $3.1 million for the year ended December 31, 2008, compared to total revenues of $14.6 million for the year ended December 31, 2007. Revenues in both the year ended December 31, 2008 and 2007 were primarily in connection with the Company's collaboration agreement with sanofi-aventis. As a result of sanofi-aventis' decision to terminate its participation in the UVIDEM development program in December 2007, we will not receive further payments or revenues from sanofi-aventis related to UVIDEM.

Research and development (R&D) expenses in the quarter ended December 31, 2008 decreased to $1.0 million from $5.2 million in the prior year period. For the year ended December 31, 2008, R&D expenses decreased to $11.2 million from $22.3 million in 2007. The decreased R&D spending during the periods was related to a reduction in spending on MEPACT (mifamurtide) and UVIDEM development, as well as reductions associated with lower headcount and closing of our Paris, France office.

Selling and marketing and general and administrative (SG&A) expenses were $3.0 million for the quarter ended December 31, 2008 compared with $2.9 mill
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Palo Alto, Calif. (PRWEB) November 20, 2014 ... (CHI), a nonprofit, public policy research organization representing ... and pharmaceutical firms, and PwC US ... other states in life sciences industry growth. The ... and 2013. The 2015 California Biomedical Industry ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 2014 ... Ferrocyanide Industry” is a professional and in-depth research ... Sodium ferrocyanide information, like its definition, classification, ... industry overview. This report covers the international market ... global (such as the US, Europe, Asia, China, ...
(Date:11/21/2014)... ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and nine month periods ended September 30, 2014.  Biorem,s complete 2014 ... ( www.sedar.com ). Financial Summary:Three-months ended September ... except per share data) , 2014 , ... 2,282 , 5,281 , 6,715 ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... YORK, Aug. 10 ExL Pharma is pleased ... many of the leading issues that are,impacting the ... offer educational and networking opportunities for Clinical,Marketing, R&D, ... biotech and medical technology companies. Listed below ...
... Genmab,s Partner Roche has Filed an IND With the US FDA for ... ... A/S (OMX: GEN),announced today that its partner Roche has filed an Investigational ... antibody developed under the companies, collaboration. Genmab will,receive a milestone payment from ...
... Reliant Pharmaceuticals,Inc. today announced that it has filed ... Exchange Commission for an initial public offering,of its common ... issued common stock and that certain stockholders may sell,a ... Goldman, Sachs & Co. and Merrill Lynch & ...
Cached Biology Technology:Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Roche Files IND for Second Genmab Antibody 2Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering 2
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/7/2014)... Florida , November 6, 2014 ... authentication for better mobile security revolutionizing online transactions.  Companies in ... Alibaba Holdings Ltd. (NYSE: BABA ), Google Inc. ... MSFT ), eBay Inc. (NASDAQ: EBAY ) and ... NXTD and NXTDW), a biometric authentication company focused ...
(Date:11/6/2014)... an asset for a predator. Except when that predator runs ... beetle, relative to its size, is the fastest creature on ... lengths per second (at about five miles per hour). The ... the sprinting gold from the tiger beetle, a person would ... tiger beetle has a problem. At peak speeds, everything becomes ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6The tiger beetle: Too fast to see 2
... of microbes colonizing and thriving on flecks of plastic ... of microbial communities that they have dubbed the "plastisphere." ... Environmental Science & Technology , the scientists say the ... and raises a host of questions: How will it ...
... of antibacterial soaps containing the chemical triclocarban may harm ... University of Tennessee, Knoxville. The study, which was ... may reduce the survival rates of babies. Rebekah ... degree in public health and nutrition, and Jiangang Chen, ...
... available in French . ... and Alberta Innovates Bio Solutions have partnered to support a $1.4 ... foodborne illness caused by Listeria bacteria. , The project, ... sequence and map the genomes of many Listeria strains ...
Cached Biology News:Scientists discover thriving colonies of microbes in ocean 'plastisphere' 2UT study: Chemical in antibacterial soaps may harm nursing babies 2New genomics research project to eliminate Listeria from food supply 2
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
Contact us for more information...
Contact us for more information...
Biology Products: